Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)

2 weeks ago 9

Soumya Eswaran

Thu, December 4, 2025 astatine 8:34 AM CST 3 min read

Harding Loevner, an plus absorption company, released its “Global Equity Strategy” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The money returned 2.62% gross (2.52% net) successful the 3rd 4th of 2025, compared to a 7.74% instrumentality for the MSCI All Country World Index and 7.36% summation for the MSCI World Index. YTD, the strategy roseate 10.61% (net) compared to 18.86% and 17.83% for the indexes. The steadfast highlighted successful the missive that the past six months represented 1 of the strongest momentum phases successful implicit 70 years. Since the opening of the year, high-momentum stocks person outperformed low-momentum stocks by a singular 45 percent points, with overmuch of the maturation driven by advancements successful AI. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Harding Loevner Global Equity Strategy highlighted stocks specified arsenic Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is simply a biotechnology institution focusing connected processing and commercializing therapies for treating cystic fibrosis (CF). The one-month instrumentality of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 11.26%, and its shares gained 0.70% of their worth implicit the past 52 weeks. On December 03, 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) banal closed astatine $463.13 per share, with a marketplace capitalization of $117.5 billion.

Harding Loevner Global Equity Strategy stated the pursuing regarding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) successful its 3rd 4th 2025 capitalist letter:

"Health Care is the portfolio's fourth-largest assemblage holding and 1 of its largest overweights. Our 11 Health Care companies span pharmaceuticals, biotechnology, beingness sciences, and instrumentality and services. They see Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a US institution that has a near-monopoly presumption successful cystic-fibrosis treatments and a research-and-development motor that offers optionality connected aboriginal drugs; Vertex's net should compound astir 15% annually implicit the adjacent 5 years."

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 61 hedge money portfolios held Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) astatine the extremity of the 3rd quarter, which was 53 successful the erstwhile quarter. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) delivered $3.08 cardinal successful gross successful the 3rd quarter, representing a 11% maturation compared to Q3 2024. While we admit the imaginable of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.